Cascadian Therapeutics Company Profile (NASDAQ:CASC)

About Cascadian Therapeutics (NASDAQ:CASC)

Cascadian Therapeutics logoCascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company's clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor. The Company's ONT-10 is a therapeutic vaccine targeting the Mucin 1 peptide antigen (MUC1). The Company is engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 (Chk1) kinase inhibitor and protocell technology. The Company completed the evaluation of approximately two dosing cohorts in its Phase Ib trial of ONT-10 in combination with the anti-CD27 T-cell agonist antibody varlilumab in collaboration with other company. The Company has completed Phase I trial of ONT-380, with both dose-escalation and expansion components. The Company has initiated Phase Ib trials of ONT-380.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:CASC
  • CUSIP: 68232410
  • Web: www.cascadianrx.com
Capitalization:
  • Market Cap: $202.72 million
  • Outstanding Shares: 50,553,000
Average Prices:
  • 50 Day Moving Avg: $3.71
  • 200 Day Moving Avg: $3.92
  • 52 Week Range: $3.18 - $10.98
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.68
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $2.80 per share
  • Price / Book: 1.43
Profitability:
  • EBIDTA: ($47,290,000.00)
  • Return on Equity: -42.30%
  • Return on Assets: -39.68%
Debt:
  • Current Ratio: 16.45%
  • Quick Ratio: 16.45%
Misc:
  • Average Volume: 361,623 shs.
  • Beta: 2.28
  • Short Ratio: 9.61
 

Frequently Asked Questions for Cascadian Therapeutics (NASDAQ:CASC)

What is Cascadian Therapeutics' stock symbol?

Cascadian Therapeutics trades on the NASDAQ under the ticker symbol "CASC."

How were Cascadian Therapeutics' earnings last quarter?

Cascadian Therapeutics, Inc. (NASDAQ:CASC) announced its earnings results on Tuesday, August, 8th. The company reported ($0.30) EPS for the quarter, beating the Zacks' consensus estimate of ($0.36) by $0.06. During the same quarter in the previous year, the firm earned ($1.57) EPS. View Cascadian Therapeutics' Earnings History.

Where is Cascadian Therapeutics' stock going? Where will Cascadian Therapeutics' stock price be in 2017?

5 brokerages have issued twelve-month target prices for Cascadian Therapeutics' shares. Their forecasts range from $4.00 to $10.00. On average, they expect Cascadian Therapeutics' stock price to reach $6.00 in the next year. View Analyst Ratings for Cascadian Therapeutics.

What are analysts saying about Cascadian Therapeutics stock?

Here are some recent quotes from research analysts about Cascadian Therapeutics stock:

  • 1. Cantor Fitzgerald analysts commented, "Pooled analysis from Phase Ib trial in HER2+ metastatic breast cancer patients with or without brain metastases demonstrated similarity in PFS between two groups (264P), which is a secondary endpoint in the HER2CLIMB trial." (9/11/2017)
  • 2. According to Zacks Investment Research, "Cascadian Therapeutics, Inc. is a biopharmaceutical company specializing in developing innovative therapeutic product candidates for the treatment of cancer. The company's product candidate is ONT-380, an orally active and selective small molecule HER2 inhibitor which is in preclinical trial stage. Cascadian Therapeutics, Inc., formerly known as Oncothyreon Inc., is headquartered in Seattle, Washington. " (8/11/2017)
  • 3. Cowen and Company analysts commented, "CASC reported 1Q financials and provided a pipeline update." (5/9/2017)

Who are some of Cascadian Therapeutics' key competitors?

Who are Cascadian Therapeutics' key executives?

Cascadian Therapeutics' management team includes the folowing people:

  • Christopher S. Henney Ph.D., Chairman of the Board
  • Scott D. Myers, President, Chief Executive Officer, Director
  • Julia Marie Eastland, Chief Financial Officer, Vice President - Corporate Development, Secretary
  • Gary W. Christianson, Chief Operating Officer
  • Scott Peterson Ph.D., Chief Scientific Officer
  • Robert W. Azelby, Director
  • Gwendolyn A. Fyfe M.D., Independent Director
  • Steven P. James, Independent Director
  • Ted W. Love M.D., Independent Director
  • Daniel Keith Spiegelman, Independent Director

Who owns Cascadian Therapeutics stock?

Cascadian Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include NEA Management Company LLC (18.41%), Redmile Group LLC (7.39%), EcoR1 Capital LLC (5.93%), Vanguard Group Inc. (3.59%), Sandia Holdings LLC (1.88%) and Sphera Funds Management LTD. (1.38%). Company insiders that own Cascadian Therapeutics stock include Christopher S Henney, Gwen A Fyfe, Scott Dunseth Myers and Ted W Love. View Institutional Ownership Trends for Cascadian Therapeutics.

Who sold Cascadian Therapeutics stock? Who is selling Cascadian Therapeutics stock?

Cascadian Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC, EcoR1 Capital LLC and DAFNA Capital Management LLC. View Insider Buying and Selling for Cascadian Therapeutics.

Who bought Cascadian Therapeutics stock? Who is buying Cascadian Therapeutics stock?

Cascadian Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Sandia Holdings LLC, Boston Partners, State Street Corp, Vanguard Group Inc., Northern Trust Corp, Bank of New York Mellon Corp, Sphera Funds Management LTD. and TIAA CREF Investment Management LLC. Company insiders that have bought Cascadian Therapeutics stock in the last two years include Christopher S Henney, Gwen A Fyfe, Scott Dunseth Myers and Ted W Love. View Insider Buying and Selling for Cascadian Therapeutics.

How do I buy Cascadian Therapeutics stock?

Shares of Cascadian Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cascadian Therapeutics' stock price today?

One share of Cascadian Therapeutics stock can currently be purchased for approximately $4.01.


MarketBeat Community Rating for Cascadian Therapeutics (NASDAQ CASC)
Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  166 (Vote Outperform)
Underperform Votes:  163 (Vote Underperform)
Total Votes:  329
MarketBeat's community ratings are surveys of what our community members think about Cascadian Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Cascadian Therapeutics (NASDAQ:CASC) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Hold (Score: 2.40)
Consensus Price Target: $6.00 (49.63% upside)

Analysts' Ratings History for Cascadian Therapeutics (NASDAQ:CASC)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/11/2017Cantor FitzgeraldReiterated RatingHold$4.00MediumView Rating Details
9/6/2017Barclays PLCInitiated CoverageUnderweight$4.00HighView Rating Details
8/9/2017Cowen and CompanyReiterated RatingBuyHighView Rating Details
4/21/2017BTIG ResearchInitiated CoverageBuyHighView Rating Details
3/11/2017Jefferies Group LLCReiterated RatingBuy$15.00 -> $10.00N/AView Rating Details
3/15/2016Raymond James Financial, Inc.Lower Price Target$5.00 -> $3.00N/AView Rating Details
12/9/2015HC WainwrightReiterated RatingBuy$5.00N/AView Rating Details
(Data available from 9/21/2015 forward)

Earnings

Earnings History for Cascadian Therapeutics (NASDAQ:CASC)
Earnings by Quarter for Cascadian Therapeutics (NASDAQ:CASC)
Earnings History by Quarter for Cascadian Therapeutics (NASDAQ CASC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2017Q2 2017($0.36)($0.30)ViewListenView Earnings Details
5/9/2017Q1 2017($0.39)($0.30)ViewListenView Earnings Details
3/9/2017Q4 2016($0.52)($0.47)ViewN/AView Earnings Details
11/7/2016Q3 2016($0.08)($0.09)ViewN/AView Earnings Details
5/9/2016Q1 2016($0.10)($0.14)ViewN/AView Earnings Details
3/14/2016Q4($0.08)($0.10)ViewN/AView Earnings Details
11/5/2015Q315($0.10)($0.05)ViewListenView Earnings Details
8/6/2015Q215($0.08)($0.11)ViewN/AView Earnings Details
5/11/2015Q115($0.08)($0.08)ViewListenView Earnings Details
3/10/2015Q414($0.09)($0.30)ViewListenView Earnings Details
11/6/2014Q314($0.11)($0.09)ViewN/AView Earnings Details
8/11/2014Q214($0.13)($0.09)ViewN/AView Earnings Details
5/1/2014Q114($0.12)($0.14)ViewN/AView Earnings Details
3/13/2014Q413($0.10)($0.09)ViewN/AView Earnings Details
11/12/2013Q3($0.11)($0.12)ViewListenView Earnings Details
8/6/2013Q2 2013($0.14)($0.28)ViewN/AView Earnings Details
5/9/2013Q1 2013($0.13)($0.14)ViewN/AView Earnings Details
3/25/2013Q412$1.09$0.50$135.60 million$123.57 millionViewN/AView Earnings Details
3/14/2013Q4 2012($0.16)($0.12)ViewN/AView Earnings Details
11/28/20121.16$1.16$137.19 millionViewN/AView Earnings Details
11/7/2012Q312($0.15)($0.15)ViewN/AView Earnings Details
8/9/2012($0.15)($0.15)ViewN/AView Earnings Details
5/7/2012($0.17)$0.21ViewN/AView Earnings Details
3/6/2012($0.15)($0.27)ViewN/AView Earnings Details
11/8/2011($0.16)$0.22ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cascadian Therapeutics (NASDAQ:CASC)
Current Year EPS Consensus Estimate: $5.02 EPS
Next Year EPS Consensus Estimate: $-1.09 EPS

Dividends

Dividend History for Cascadian Therapeutics (NASDAQ:CASC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Cascadian Therapeutics (NASDAQ:CASC)
Insider Ownership Percentage: 20.70%
Institutional Ownership Percentage: 82.55%
Insider Trades by Quarter for Cascadian Therapeutics (NASDAQ:CASC)
Institutional Ownership by Quarter for Cascadian Therapeutics (NASDAQ:CASC)
Insider Trades by Quarter for Cascadian Therapeutics (NASDAQ:CASC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/11/2017Scott Dunseth MyersInsiderBuy5,500$3.74$20,570.00View SEC Filing  
5/12/2017Scott Dunseth MyersInsiderBuy2,800$4.00$11,200.00View SEC Filing  
3/31/2017Scott Dunseth MyersInsiderBuy2,000$4.11$8,220.00View SEC Filing  
3/28/2017Gwen A FyfeDirectorBuy1,666$4.12$6,863.92View SEC Filing  
3/20/2017Scott Dunseth MyersInsiderBuy1,000$3.93$3,930.00View SEC Filing  
2/2/2017Ted W. LoveDirectorBuy23,000$4.24$97,520.00View SEC Filing  
1/30/2017Christopher S HenneyDirectorBuy25,324$4.11$104,081.64View SEC Filing  
1/27/2017Scott Dunseth MyersInsiderBuy20,500$3.76$77,080.00View SEC Filing  
8/17/2016Scott Dunseth MyersInsiderBuy45,000$1.15$51,750.00View SEC Filing  
6/28/2016Scott Dunseth MyersCEOBuy62,500$0.80$50,000.00View SEC Filing  
6/1/2015Diana HausmanInsiderBuy5,747$4.65$26,723.55View SEC Filing  
3/26/2015Daniel K SpiegelmanDirectorBuy10,000$1.59$15,900.00View SEC Filing  
3/25/2015Daniel K SpiegelmanDirectorBuy10,000$1.63$16,300.00View SEC Filing  
12/17/2014Bvf Partners L P/IlMajor ShareholderBuy378,444$1.82$688,768.08View SEC Filing  
12/15/2014Bvf Partners L P/IlMajor ShareholderBuy224,949$1.88$422,904.12View SEC Filing  
9/23/2014Jay VenkatesanEVPBuy250,000$2.00$500,000.00View SEC Filing  
7/10/2014Daniel K SpiegelmanDirectorSell3,403$1.72$5,853.16View SEC Filing  
2/20/2014Daniel K SpiegelmanDirectorSell12,780$1.96$25,048.80View SEC Filing  
11/1/2013Bvf Partners L P/IlMajor ShareholderBuy129,000$1.78$229,620.00View SEC Filing  
8/8/2013Bvf Partners P/Ilmajor shareholderBuy258,361$1.65$426,295.65View SEC Filing  
8/1/2013Bvf Partners L P/IlMajor ShareholderBuy338,087$1.74$588,271.38View SEC Filing  
6/7/2013Bvf Partners L P/IlMajor ShareholderBuy214,467$1.81$388,185.27View SEC Filing  
12/27/2012Wendy W WarrenMajor ShareholderSell57,943$64.30$3,725,734.90View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Cascadian Therapeutics (NASDAQ:CASC)
Latest Headlines for Cascadian Therapeutics (NASDAQ:CASC)
Source:
DateHeadline
finance.yahoo.com logoCascadian Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 20 at 5:43 PM
americanbankingnews.com logoCascadian Therapeutics, Inc. (CASC) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - September 13 at 2:50 AM
globenewswire.com logoTucatinib Data in Multiple Tumor Types Presented at the European Society for Medical Oncology (ESMO) 2017 Congress - GlobeNewswire (press release)
globenewswire.com - September 11 at 10:32 PM
finance.yahoo.com logoTucatinib Data in Multiple Tumor Types Presented at the European Society for Medical Oncology (ESMO) 2017 Congress
finance.yahoo.com - September 11 at 5:32 PM
americanbankingnews.com logoCascadian Therapeutics' (CASC) "Hold" Rating Reiterated at Cantor Fitzgerald
www.americanbankingnews.com - September 11 at 1:22 PM
americanbankingnews.com logoCascadian Therapeutics, Inc. (CASC) Now Covered by Analysts at Barclays PLC
www.americanbankingnews.com - September 10 at 5:52 PM
finance.yahoo.com logo2 Names Barclays Is Now Bearish On In Biotech
finance.yahoo.com - September 7 at 9:42 PM
americanbankingnews.com logoCascadian Therapeutics, Inc. (CASC) Downgraded by ValuEngine
www.americanbankingnews.com - September 3 at 7:44 PM
americanbankingnews.com logoCascadian Therapeutics' (CASC) "Hold" Rating Reaffirmed at Cantor Fitzgerald
www.americanbankingnews.com - August 31 at 9:50 AM
streetinsider.com logoCascadian Therapeutics (CASC) Announces Poster Presentations on Tucatinib in Multiple Tumor Types at ESMO
www.streetinsider.com - August 29 at 2:55 AM
globenewswire.com logoCascadian Therapeutics Announces Poster Presentations on ... - GlobeNewswire (press release)
globenewswire.com - August 28 at 9:53 PM
finance.yahoo.com logoCascadian Therapeutics Announces Poster Presentations on Tucatinib in Multiple Tumor Types at the European Society for Medical Oncology (ESMO) 2017 Congress
finance.yahoo.com - August 28 at 4:52 PM
americanbankingnews.com logoCascadian Therapeutics, Inc. (CASC) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - August 19 at 2:42 AM
americanbankingnews.com logoCascadian Therapeutics, Inc. (NASDAQ:CASC) Insider Acquires $20,570.00 in Stock
www.americanbankingnews.com - August 15 at 12:16 AM
americanbankingnews.com logoCascadian Therapeutics, Inc. (NASDAQ:CASC) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - August 11 at 6:42 PM
americanbankingnews.com logoCascadian Therapeutics, Inc. (NASDAQ:CASC) Issues Quarterly Earnings Results, Beats Expectations By $0.06 EPS
www.americanbankingnews.com - August 10 at 4:04 PM
finance.yahoo.com logoEdited Transcript of CASC earnings conference call or presentation 8-Aug-17 8:30pm GMT
finance.yahoo.com - August 9 at 5:10 PM
finance.yahoo.com logoCascadian Therapeutics reports 2Q loss
finance.yahoo.com - August 9 at 5:10 PM
globenewswire.com logoCascadian Therapeutics Reports Second Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - August 8 at 4:38 PM
finance.yahoo.com logoCascadian Therapeutics Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 8 at 4:38 PM
globenewswire.com logoCascadian Therapeutics to Report Second Quarter 2017 Financial Results on August 8, 2017 - GlobeNewswire (press release)
globenewswire.com - August 1 at 10:46 PM
finance.yahoo.com logoCascadian Therapeutics to Report Second Quarter 2017 Financial Results on August 8, 2017
finance.yahoo.com - August 1 at 5:44 PM
americanbankingnews.com logoCascadian Therapeutics, Inc. (CASC) Short Interest Down 30.2% in July
www.americanbankingnews.com - July 29 at 7:15 AM
americanbankingnews.com logoCascadian Therapeutics, Inc. (CASC) Expected to Post Earnings of -$0.25 Per Share
www.americanbankingnews.com - July 29 at 12:21 AM
americanbankingnews.com logoCascadian Therapeutics, Inc. (NASDAQ:CASC) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - July 25 at 10:40 AM
americanbankingnews.com logoCascadian Therapeutics, Inc. (NASDAQ:CASC) Upgraded at Zacks Investment Research
www.americanbankingnews.com - July 17 at 5:20 PM
americanbankingnews.com logoShort Interest in Cascadian Therapeutics, Inc. (CASC) Grows By 206.8%
www.americanbankingnews.com - July 14 at 7:34 AM
streetinsider.com logoCascadian Therapeutics (CASC) Announces Positive Regulatory Update for Tucatinib Following Discussions with EMA
www.streetinsider.com - July 12 at 3:58 AM
reuters.com logoBRIEF-Cascadian Therapeutics announces positive regulatory update for Tucatinib in Europe - Reuters
www.reuters.com - July 11 at 5:57 PM
globenewswire.com logoCascadian Therapeutics Announces Positive Regulatory Update for Tucatinib in Europe - GlobeNewswire (press release)
globenewswire.com - July 11 at 5:57 PM
finance.yahoo.com logoCascadian Therapeutics Announces Positive Regulatory Update for Tucatinib in Europe
finance.yahoo.com - July 11 at 5:57 PM
americanbankingnews.com logoZacks: Analysts Anticipate Cascadian Therapeutics, Inc. (NASDAQ:CASC) to Post -$0.25 Earnings Per Share
www.americanbankingnews.com - July 4 at 8:10 PM
americanbankingnews.com logoCascadian Therapeutics, Inc. (CASC) Short Interest Update
www.americanbankingnews.com - June 14 at 7:08 AM
americanbankingnews.com logoCascadian Therapeutics, Inc. (CASC) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - June 11 at 9:34 PM
americanbankingnews.com logoCascadian Therapeutics Inc (CASC) Expected to Post Earnings of -$0.25 Per Share
www.americanbankingnews.com - June 8 at 8:24 PM
globenewswire.com logoCascadian Therapeutics' Lead Candidate, Tucatinib, Receives Orphan Drug Designation from FDA for Treatment of ... - GlobeNewswire (press release)
globenewswire.com - June 8 at 5:08 PM
finance.yahoo.com logoCascadian Therapeutics’ Lead Candidate, Tucatinib, Receives Orphan Drug Designation from FDA for Treatment of Breast Cancer Patients with Brain Metastases
finance.yahoo.com - June 8 at 5:07 PM
seekingalpha.com logoCascadian Therapeutics (CASC) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - June 7 at 4:27 PM
americanbankingnews.com logoCascadian Therapeutics Inc (CASC) Short Interest Update
www.americanbankingnews.com - June 4 at 9:46 AM
americanbankingnews.com logoCascadian Therapeutics Inc (CASC) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - June 2 at 4:50 PM
nasdaq.com logoCascadian Therapeutics to Present at Jefferies 2017 Healthcare Conference - Nasdaq
www.nasdaq.com - May 31 at 4:12 PM
finance.yahoo.com logoCascadian Therapeutics to Present at Jefferies 2017 Healthcare Conference
finance.yahoo.com - May 31 at 10:23 AM
americanbankingnews.com logoCascadian Therapeutics Inc (CASC) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 19 at 5:20 PM
americanbankingnews.com logoInsider Buying: Cascadian Therapeutics Inc (CASC) Insider Buys 2,800 Shares of Stock
www.americanbankingnews.com - May 16 at 8:44 PM
americanbankingnews.com logoBrokers Offer Predictions for Cascadian Therapeutics Inc's FY2017 Earnings (CASC)
www.americanbankingnews.com - May 15 at 8:50 AM
americanbankingnews.com logo Brokerages Expect Cascadian Therapeutics Inc (CASC) to Announce -$0.26 EPS
www.americanbankingnews.com - May 12 at 4:02 PM
News IconCORRECTED-BRIEF-Cascadian says stockholder Growth Equity Opportunities Fund IV has option to resell 1.82 mln of co's shares (May 8)
www.businessinsider.com - May 11 at 2:22 AM
reuters.com logoBRIEF-Cascadian Therapeutics reports Q1 loss per share of $0.30 - Reuters
www.reuters.com - May 10 at 8:33 AM
americanbankingnews.com logoCascadian Therapeutics Inc (CASC) Earns Hold Rating from Cantor Fitzgerald
www.americanbankingnews.com - May 10 at 7:36 AM
finance.yahoo.com logoEdited Transcript of CASC earnings conference call or presentation 9-May-17 12:30pm GMT
finance.yahoo.com - May 9 at 9:09 PM

Social

Chart

Cascadian Therapeutics (CASC) Chart for Thursday, September, 21, 2017

This page was last updated on 9/21/2017 by MarketBeat.com Staff